Literature DB >> 6971488

Antibodies against polyriboadenylic acid in systemic lupus erythematosus and rheumatoid arthritis demonstrated by ELISA. Prevalence of and relation to antibodies against DNA and extractable nuclear antigens.

M Gripenberg, H Piirainen, E Linder.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) for the demonstration of class-specific antibodies against polyriboadenylic acid (poly-(A)) is described. The results revealed the presence of IgG-anti-poly(A) antibodies in 63% (22/35) of patients with systemic lupus erythematosus (SLE) and in 25% (22/88) of patients with rheumatoid arthritis (RA), the mean antibody level being significantly higher in the SLE patients. Anti-poly(A) antibodies of IgM class were seen in 15 and 17% of the patients, respectively. The prevalence of anti-poly(A) and anti-ssDNA antibodies of IgG class was similar in the patients with SLE, but the occurrence of antibodies against poly(A), DNA and extractable nuclear antigens varied independently of each other. In the RA-patients, a positive correlation was seen between the levels of IgG-anti-ssDNA and IgG-anti-poly(A) antibodies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971488

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  5 in total

Review 1.  B-cell epitopes of RNA autoantigens.

Authors:  R M Hoet; W J van Venrooij
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  Monoclonal anti-poly(rA) hybridoma antibodies from an autoimmune MRL/MpJ-lpr/lpr mouse.

Authors:  H Dang; M Fischbach; M Erdos; N Talal
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

3.  Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases.

Authors:  F Blanco; J Kalsi; D A Isenberg
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

4.  Enzyme-linked immunosorbent assays for antibodies to poly(A), poly dAT and histones: possibly useful tools for the evaluation of prognosis and disease activity in systemic lupus erythematosus.

Authors:  T Helve; M Gripenberg; P Kurki; A M Teppo; O Wegelius
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

5.  Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; A M Teppo; C Friman
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.